CAMBRIDGE, Mass., Oct. 27,
2022 /PRNewswire/ -- Obsidian Therapeutics, Inc., a
clinical-stage biotechnology company pioneering engineered cell and
gene therapies, today announced that Bristol Myers Squibb
(NYSE:BMY) has opted to extend the term of the parties' multi-year
strategic collaboration for the discovery and development of novel,
regulated cell therapies that utilize Obsidian's cytoDRiVE®
technology for the controlled expression of the immune enhancer
CD40L. Today's announcement builds on the existing relationship
between Obsidian and Bristol Myers Squibb, initiated in 2019, and
follows the first opt-in decision by Bristol Myers Squibb in
2020.
"We are delighted to extend our productive strategic partnership
with Bristol Myers Squibb, an industry leader in the field, to
advance next-generation cell therapies to patients with solid
tumors and other malignancies," said Paul
K. Wotton, Ph.D., Chief Executive Officer of Obsidian
Therapeutics. "This announcement comes at an exciting time for
Obsidian as our own lead program using cytoDRiVE technology enters
the clinic."
This multi-year collaboration extension provides Bristol Myers
Squibb with the exclusive option to in-license worldwide rights for
cell therapy candidates incorporating Obsidian's cytoDRiVE
technology to control the expression of CD40L for the treatment of
cancer. Under the terms of the agreement, Obsidian is eligible to
receive potential future milestone and royalty payments.
About Obsidian Therapeutics
Obsidian Therapeutics, Inc. is a clinical biotechnology company
pioneering engineered cell and gene therapies to deliver
transformative outcomes for patients with intractable diseases.
Obsidian's proprietary cytoDRiVE® technology provides a way to
precisely control the timing and level of protein function by using
FDA approved small molecules. Obsidian is headquartered in
Cambridge, Mass. The Company has
collaborations with Bristol Myers Squibb and Vertex
Pharmaceuticals. For more information, please visit
www.obsidiantx.com and follow us on LinkedIn and Twitter.
Obsidian's lead program, OBX-115, is a novel engineered
tumor-infiltrating lymphocyte (TIL) therapy armed with regulated
membrane-bound IL15 that is designed to remove the need for
concomitant IL2 therapy, a toxic and costly requirement for
conventional TILs. OBX-115 preclinical data have demonstrated
enhanced TIL persistence, potency and improved tumor control
compared to unengineered TILs, which is anticipated to improve
clinical outcomes in patients suffering from metastatic melanoma
and other solid tumors. FDA granted IND clearance for OBX-115 in
July 2022. The Phase I FIH clinical
trial for OBX-115 is currently recruiting patients. Information
regarding the clinical trial is available at
clinicaltrials.gov: NCT05470283.
Obsidian Therapeutics Media Contact:
Erica Fiorini, Ph.D., or Liz Philips
Russo Partners, LLC
Erica.Fiorini@russopartnersllc.com
Elizabeth.Phillips@russopartnersllc.com
+1 (914) 310-8172
View original content to download
multimedia:https://www.prnewswire.com/news-releases/obsidian-therapeutics-announces-extension-of-multi-year-collaboration-agreement-with-bristol-myers-squibb-301660585.html
SOURCE Obsidian Therapeutics